A University of Chicago trial is drawing attention for a type 1 diabetes treatment that moved fast. New findings say all 10 initial participants, who had type 1 diabetes for an average of 33 years, ...

Lilly is betting big on retatrutide as the next pillar of its obesity portfolio after its weight loss injection Zepbound and ...

The first-in-class injectable could be the next big thing in diabetes and obesity treatment.

SELECT was a large study focused on obesity and cardiovascular disease in people without type 2 diabetes, but it included kidney outcomes as a secondary end point. The data showed that semaglutide ...

The AACE update to its 2026 algorithm for the management of type 2 diabetes includes a new section on diabetes classification.

With patent protection ending, Indian companies have moved quickly to introduce lower-cost versions with monthly therapy ...

One of Eli Lilly & Co.’s most highly anticipated experimental medicines helped diabetic patients lose more weight than any ...

The market for obesity and diabetes treatments remains scorching hot, funneling billions in sales to Eli Lilly and fueling a bidding war over another drugmaker. Lilly said Thursday that its ...

Researchers found that the risk of type 2 diabetes varies among young adults. Those with high fasting glucose who qualified for GLP-1 treatment had a higher risk of type 2 diabetes, suggesting that ...

A one-size-fits-all approach to prediabetes treatment may miss the opportunity to implement an early, more intensive, ...

Obesity and type 2 diabetes are deeply interconnected. Yet, many diabetes prevention programs fail to adequately treat ...

Leading Sun Pharmaceutical Industries, Zydus Lifesciences and Dr Reddy's Laboratories have launched generic semaglutide injections in India, offering more affordable treatment options for patients ...